Point72 Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Point72 Asset Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,000,000	Closed	-$25.5M	–	1386
2021 Q3	$25.5M	Hold	1,000,000	–	–	0.11%	243
2021 Q2	$35M	Buy	+1,000,000	New	+$39M	0.16%	170
2020 Q1	–	Sell	-250,000	Closed	-$19.9M	–	1175
2019 Q4	$19.9M	Buy	+250,000	New	+$14.8M	0.1%	259
2018 Q3	–	Sell	-726,700	Closed	-$32.8M	–	1283
2018 Q2	$32.8M	Buy	726,700 +476,700	+191%	+$21.7M	0.13%	200
2018 Q1	$12.1M	Buy	250,000 +50,000	+25%	+$2.79M	0.05%	388
2017 Q4	$7.87M	Buy	+200,000	New	+$7.47M	0.03%	496

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management's GBT Position: Q3 2022 in Review

Point72 Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 1,524,485 shares — an estimated $48.7M sold.

Point72 Asset Management first reported a position in GBT in Q1 2016 and held it in 17 quarters. The position peaked at $72.2M in Q2 2021. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

Point72 Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Point72 Asset Management sold 1,524,485 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $48.7M.
Point72 Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 17 quarters.
Point72 Asset Management's Global Blood Therapeutics, Inc. position peaked at $72.2M in Q2 2021.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Point72 Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.